Healthtech funding in Q1 2023
European Healthtech startup funding raised during Q1 2023.
In Q1 2023, 175 European Healthtech companies closed 177 funding rounds and raised €1.4B in equity funding (excluding debt and grants), down 35.0% versus Q1 2022. Debt rounds added €194M. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.4B
-35.0% vs Q1 2022 · excl. debt & grants · +€194M debt
Funding rounds
177
+3.5% vs Q1 2022
Companies
175
Top country
UK
Rank among sectors
#3
10.4% of sector funding
Debt financing
€194M
11.9% of total
Top-10 round share
47.4%
of disclosed capital
Rounds ≥ €100M
4
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q1 2023 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €538M | 66 |
| Feb | €580M | 54 |
| Mar | €517M | 57 |
Top countries
by € raisedHealthtech — top countries by capital, Q1 2023 — interactive chart.
Data table
| Healthtech — top countries by capital, Q1 2023 | |
|---|---|
| UK | €341M |
| Germany | €273M |
| France | €250M |
| Switzerland | €227M |
| Denmark | €181M |
| Italy | €74M |
| Belgium | €56M |
| Ireland | €45M |
Stage mix
by € raisedHealthtech — stage mix, Q1 2023 — interactive chart.
Data table
| Healthtech — stage mix, Q1 2023 | |
|---|---|
| Other | €425M |
| Series B | €387M |
| Series C | €281M |
| Debt | €194M |
| Series A | €150M |
| Seed | €73M |
| Series D+ | €72M |
| Grant | €38M |
| Pre-Seed | €14M |
| Growth/Late | €1.0M |
Exits & M&A
17 Acquisition17 exits · €170M disclosed.
| Verogen | Acquisition | Jan 2023 | €140M |
| Diamond Whites | Acquisition | Feb 2023 | €30M |
Top deals
largest disclosed rounds in Q1 2023| Company | Stage | Date | Amount |
|---|---|---|---|
| Evotec | Debt | Feb 2023 | €150M |
| Amolyt Pharma | Series C | Jan 2023 | €129M |
| Hemab Therapeutics | Series B | Feb 2023 | €127M |
| Noema Pharma | Series B | Mar 2023 | €105M |
| SoniVie | Series C | Jan 2023 | €56M |
| Grey Wolf Therapeutics | Series B | Jan 2023 | €45M |
| Medwing | Series C | Mar 2023 | €44M |
| Peppy | Series B | Jan 2023 | €42M |
| Lunaphore Technologies | Series D+ | Mar 2023 | €40M |
| Evosep | Other | Jan 2023 | €37M |
| Perspectum | Series C | Jan 2023 | €34M |
| Owkin | Grant | Mar 2023 | €33M |
| Xeltis | Series D+ | Feb 2023 | €32M |
| Prokarium | Other | Feb 2023 | €28M |
| ExeVir Bio | Debt | Jan 2023 | €25M |
Top investors
most active in Q1 2023, by deal count- High-Tech Gründerfonds (HTGF)5 deals
- Sofinnova Partners5 deals
- Andera Partners4 deals
- European Innovation Council (EIC)4 deals
- Novo Holdings4 deals
- Scottish Enterprise4 deals
- Bpifrance3 deals
- Calm Storm Ventures3 deals
- EFI Lake Geneva Ventures3 deals
- Kurma Partners3 deals